Abstract
Introduction: Although sentinel node biopsy with completion lymphadenectomy in node-positive patients (SLND) has been widely adopted in the management of patients with early stage melanoma, reports detailing the outcome of patients after SLND are limited. To address this issue, we analyzed our experience with SLND and provided a comparison to patients treated with elective lymph node dissection (ELND).
Methods: All patients who underwent SLND (1991–1998) and ELND (1974–1994) were identified from single institution melanoma databases.
Results: A total of 152 and 329 patients with early-stage melanoma of the extremity underwent SLND and ELND, respectively. Nodal metastases were present in 44 of 329 ELND patients (13%) and in 31 of 152 SLND patients (20%). Early relapse-free and disease-specific survivals were similar for the entire population, although in patients at higher risk for recurrence (age >50 years, thickness >3.0 mm), there was an increased rate of relapse in the SLND group (P = .04). Among all sites of early recurrences, locoregional sites were more common in patients undergoing SLND (72%) compared with ELND (39%, P < .01). SLN-negative patients with nodal recurrence had evidence of metastases on retrospective enhanced pathologic analysis in four of seven cases.
Conclusions: Although overall relapse-free and disease-specific survivals are similar, there is a higher rate of relapse in a subset of SLND node-negative patients who are at high risk for nodal metastases. ELND and SLNB should not be thought of as equivalent approaches until studies with longer follow-up are available.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Landis S, Murray T, Bolden S, Wingo P. Cancer statistics 1999. CA Cancer J Clin 1999; 49: 8–31.
Drepper H, Kohler C, Bastian B, et al. Benefit of elective lymph node dissection in subgroups of melanoma patients. Cancer 1993; 72: 741–9.
McCarthy W, Shaw H, Milton G. Efficacy of elective lymph node dissection in 2,347 patients with clinical stage I malignant melanoma. Surg Gynecol Obstet 1985; 161: 575–80.
Rompel R, Garbe C, Buttner P, et al. Elective lymph node dissection in primary malignant melanoma: a matched-pair analysis. Melanoma Res 1995; 5: 189–94.
Wanebo H, Woodruff J, Fortner J. Malignant melanoma of the extremities: a clinicopathologic study using levels of invasion (microstage). Cancer 1975; 35: 666–76.
Reintgen D, Cox E, McCarty KJ, Vollmer R, Seigler H. Efficacy of elective lymph node dissection in patients with intermediate thickness primary melanoma. Ann Surg 1983; 198: 379–85.
Morton D, Wen D, Wong J, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992; 127: 392–9.
Reintgen D, Cruse C, Wells K, et al. The orderly progression of melanoma nodal metastases. Ann Surg 1994; 220: 759–67.
Thompson J, McCarthy W, Bosch C, et al. Sentinel lymph node status as an indicator of the presence of metastatic melanoma in regional lymph nodes. Melanoma Res 1995; 5: 255–60.
Balch C, Soong S, Bartolucci A, et al. Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann Surg 1996; 224: 255–66.
Cascinelli N, Morabito A, Santinami M, Mackie R, Felli F. Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial. Lancet 1998; 351: 793–6.
Kirkwood J, Strawderman M, Ernstoff M, Smith T, Borden E, Blum R. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996; 14: 7–17.
Gershenwald J, Thompson W, Mansfield P, et al. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 1999; 17: 976–83.
Gadd M, Cosimi A, YuJ, et al. Outcome of patients with melanoma and histologically negative sentinel lymph nodes. Arch Surg 1999; 134: 381–7.
Essner R, Conforti A, Kelley M, et al. Efficacy of lymphatic mapping, sentinel lymphadenectomy, and selective complete lymph node dissection as a therapeutic procedure for early-stage melanoma. Ann Surg Oncol 1999; 6: 442–9.
Slingluff C, Stidham K, Ricci W, Stanley W, Seigler H. Surgical management of regional lymph nodes in patients with melanoma: experience with 4682 patients. Ann Surg 1994; 219: 120–30.
Gershenwald J, Colome M, Lee J, et al. Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. J Clin Oncol 1998; 16: 2253–2260.
Shivers S, Wang X, LiW, et al. Molecular staging of malignant melanoma: correlation with clinical outcome. JAMA 1998; 280: 1410–5.
Bostick P, Morton D, Turner R, et al. Prognostic significance of occult metastases detected by sentinel lymphadenectomy and reverse transcriptase-polymerase chain reaction in early-stage melanoma patients. J Clin Oncol 1999; 17: 3238–44.
McCarthy W, Shaw H, Thompson J, Milton G. Time and frequency of recurrence of cutaneous stage I malignant melanoma with guidelines for follow-up study. Surg Gynecol Obstet 1988; 166: 497–502.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Clary, B.M., Mann, B., Brady, M.S. et al. Early Recurrence After Lymphatic Mapping and Sentinel Node Biopsy in Patients With Primary Extremity Melanoma: A Comparison With Elective Lymph Node Dissection. Ann Surg Oncol 8, 328–337 (2001). https://doi.org/10.1007/s10434-001-0328-6
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s10434-001-0328-6